36760-19-7

Basic information

• Product Name: 5-BROMO-3-CHLORO-1H-INDAZOLE
• Synonyms: 5-BROMO-3-CHLORO-1H-INDAZOLE;5-BROMO-3-CHLOROINDAZOLE;5-Bromo-3-chloro-1H-indaz...;5-Bromo-3-chloro-1H-indazole 95%;1H-Indazole,5-broMo-3-chloro-
• CAS NO: 36760-19-7
• Molecular Formula: C₇H₄BrClN₂
• Molecular Weight: 231.48
• Product Categories: Building Blocks;Indazole;Indazoles
• Mol File: 36760-19-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 368.5 °C at 760 mmHg
• Flash Point: 176.6 °C
• Appearance: /
• Density: 1.878 g/cm³
• Vapor Pressure: 2.7E-05mmHg at 25°C
• Refractive Index: 1.73
• Storage Temp.: 2-8°C
• PKA: 10.67±0.40(Predicted)
• CAS DataBase Reference: 5-BROMO-3-CHLORO-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-CHLORO-1H-INDAZOLE(36760-19-7)
• EPA Substance Registry System: 5-BROMO-3-CHLORO-1H-INDAZOLE(36760-19-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 36760-19-7(Hazardous Substances Data)

Usage

General Description

5-BROMO-3-CHLORO-1H-INDAZOLE is a chemical compound with the molecular formula C7H4BrClN2. It is a heterocyclic compound containing a five-membered ring fused to a six-membered ring, with bromine and chlorine substituents on the five-membered ring. 5-BROMO-3-CHLORO-1H-INDAZOLE is widely used in the pharmaceutical industry as a building block for the synthesis of various organic compounds, including pharmaceutical drugs and agrochemicals. It exhibits potential pharmacological activities, including antibacterial, antifungal, and antiparasitic properties. Additionally, it is utilized in research and development for the discovery of new drug candidates and bioactive compounds.

InChI:InChI=1/C7H4BrClN2/c8-4-1-2-6-5(3-4)7(9)11-10-6/h1-3H,(H,10,11)

Upstream product

• 53857-57-1 5-bromo-1H-indazole 
• 29110-74-5 3-chloroindazole 

Downstream Products

• 1613639-49-8 3-chloro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole 
• 1613639-00-1 (R)-2-[5-(3-chloro-1H-indazol-5-yl)pyridin-3-ylamino]-2-phenylethanol 
• 1613639-36-3 (R)-2-[5-(3-chloro-1H-indazol-5-yl)pyridin-3-ylamino]-2-phenylacetamide 
• 1613639-37-4 (S)-2-[5-(3-chloro-1H-indazol-5-yl)pyridin-3-ylamino]-2-phenylacetamide 
• 929617-36-7 tert-butyl 5-bromo-3-chloro-1H-indazole-1-carboxylate 

Relevant articles and documents

FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR

Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an A2A receptor.

SODIUM CHANNEL BLOCKERS

The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav 1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate,

Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt

Thr-211 is one of three different amino acid residues in the kinase domain of protein kinase B/Akt as compared to protein kinase A (PKA), a closely related analog in the same AGC family. In an attempt to improve the potency and selectivity of our indazole-pyridine series of Akt inhibitors over PKA, efforts have focused on the incorporation of a chemical functionality to interact with the hydroxy group of Thr-211. Several substituents including an oxygen anion, amino, and nitro groups have been introduced at the C-6 position of the indazole scaffold, leading to a significant drop in Akt potency. Incorporation of a nitrogen atom into the phenyl ring at the same position (i.e., 9f) maintained the Akt activity and, in some cases, improved the selectivity over PKA. The structure-activity relationships of the new pyridine-pyrazolopyridine series of Akt inhibitors and their structural features when bound to PKA are also discussed.